Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscopic improvement and 30.2% achieving clinical remission at the highest dose ...

NEWARK, CA / ACCESSWIRE / November 21, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced the selection of PN-881, a potential best-in-class oral peptide ...

Icotrokinra demonstrated superior skin clearance at Weeks 16 and 24 compared to deucravacitinib and similar adverse event rates to placebo in Phase 3 ICONIC-ADVANCE studies Icotrokinra also showed ...

NEWARK, Calif., May 8, 2019 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced the expansion of its worldwide license and collaboration agreement with Janssen Biotech, Inc.

In almost every anime and manga, the main antagonist is almost equally as responsible as the main protagonist in moving the narrative forward. But there are some shows where the imbalance of power ...

Webcast and conference call to be held be on Thursday, November 21st at 4:30 pm ET, dial in information below NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist ...

NEWARK, CALIFORNIA / ACCESS Newswire / September 15, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) announced that data from the Phase 2b ANTHEM-UC study with icotrokinra in ...

− All four key secondary endpoints were met, including EU primary endpoint and patient-reported outcomes NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, ...